| Literature DB >> 29663095 |
Abstract
BACKGROUND: Minimally invasive antral membrane balloon elevation was introduced as a less traumatic technique in sinus floor elevation surgery. This is the first systematic review to assess the results of previous studies utilizing this technique. AIMS OF THE STUDY: The objectives of this study were to assess the bone gain, sinus augmentation success rate, implant survival rate, and complications with minimally invasive antral membrane balloon elevation technique in comparison with the sinus floor elevation by traditional transalveolar technique (Summers' technique).Entities:
Keywords: MIAMBE technique; Sinus augmentation; Sinus floor elevation surgery
Year: 2018 PMID: 29663095 PMCID: PMC5902438 DOI: 10.1186/s40729-018-0123-9
Source DB: PubMed Journal: Int J Implant Dent ISSN: 2198-4034
Fig. 1Flow chart showing the search strategy
Descriptive statistics demonstrate patient characteristics and outcomes of MIAMBE technique in the selected studies
| Study | Patients | Age | Sinus augmentation success rate % | Baseline bone height (mm) | Bone gain (mm) | Antral membrane elevation (mm) | Total bone height (mm) | Inflate balloon volume | Type of graft | Membrane perforation | Test for membrane perforation | Complications | Follow-up period after operation | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | M:F | R | M | N | PR % | ||||||||||||
| Kfir et al. [ | 12 | NM | 42 ± 9 | NM | 91.6 | 3.7 ± 1.4 | NM | > 10 | 10–17 | ≤ 2.5 mL | -PRF | 1 | 8.33 | Valsalva maneuver | 1 membrane tear | 23 months | |
| 12 | NM | NM | 100 | 3.5 ± 1.3 | NM | > 10 | 10–18 | 0 | 0 | 1 mild periprocedural nosebleed | 12 months | ||||||
| Kfir et al. [ | 36 | M = 18 | 42 ± 9 | 36 | 97.2 | 3.4 ± 2.1 | NM | > 10 | 8–18 | NM | -PRF | 1 | 2.77 | Valsalva maneuver | 1 membrane tear | 6–8 months | |
| Hu et al. [ | 28 | M = 143 | 40.2 ± 12.35 | 28 | 92.85 | 4.92 ± 1.24 | NM | Mean 10.9 ± 2.06 | NM | 0.67 ± 0.17 mL | -PRF | 2 | 7.14 | Valsalva maneuver | 1 mild nosebleed after surgery | 15.9 ± 2.94 months. | |
| Kfir et al. [ | 112 | M = 50 | 44.1 ± 12.9 | NM | 97.3% initial procedural success 100% secondary procedural success | 3.8 ± 2.1 | NM | > 10 | 11–18 | NM | -PRF | 12 | 10.71 | Valsalva maneuver | 1 infection and oroantral fistula at 4 weeks | 13 months | |
| Mazor et al. [ | 20 | NM | 37–72 | 24 | 100 | 2–6 | NM | 11 | NM | NM | -PRF | 0 | 0 | Valsalva maneuver | 1 patient was allergic to the antibiotic | 18 months | |
| Petruzzi et al. [ | 40 | M = 16 | 41.5 | NM | NM | 8.00 ± 2.19 | 0.6 | ≤ 20 | 14.66 ± 1.48 | 1– ml | Calcium | 3 | 7.5 | Microscope (KarlKaps) | 1 m acrolaceration | 1 year | |
| Peñarrocha-Diago et al. [ | 6 | M = 5 | 27–51 | 6 | 83.3% for the all 6 cases 100% for the five cases | 2.1–4.1 | 7.2–10.8 | 8.7 | NM | 11.3–14.5 | NM | -ABP | 1 | 16.66 | (Medi Pack Pal) | 1 membrane tear and case aborted | 1 year after prosthetic loading |
| Gonzalez et al. [ | 14 | M = 7 | NM | NM | 71.4 | 5.2 | 8.5 | NM | NM | NM | BIO-OSS | 3 | 21.32 | An operating microscope | Failure of four cases due to mucosa perforation (21.32%) and balloon breakage (7.14%). | 1 year | |
| Dhandapani et al. [ | 9 | NM | 25–60 | 10 | 100 | 5–8 | 3–5.5 | 4.34 | ≥ 10 | 13.5–9 | 1 cc | Irradiated | 0 | 0 | NM | No complications | 6 months |
| Asmael, and Lateef [ | 13 | M = 4 | 28–57 | 17 | 100 | 2.3–7.8 | 4.9 –10.6 | 6.70 | NM | 9.8–17.2 | 0.5–1 cc | Particulate | 0 | 0 | Direct | 1 mild nasal bleeding | 1 year |
| Total : Average | 91.6 | 6.968 | 6.76 | ||||||||||||||
MIAMBE minimally invasive antral membrane balloon elevation, N number, NM not mentioned, M:F male: female numbers, M mean, R range, PRF platelets rich fibrin, PRP platelets rich plasma, ABP autogenous bone particles, PR perforation rate
Summary of the dental implants characteristics, survival rates, and failure rates with MIAMBE technique
| Study | Baseline bone height | Total | Implants survival rate % | Implant failure rate % | Implant lengths | Implant diameters | Timing of failure | Follow-up period after operation | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 12 | 3.7 ± 1.4 mm | Mean ± SD | NM | 1 | NM | 13, 17.1 mm | 3.75, 5 mm | 2 weeks after procedure | 23 months | |
| 12 | 3.5 ± 1.3 mm | Mean ± SD | 100 | 0 | 0 | 13, 17.1 mm | 3.75, 5 mm | 12 months | ||
| 36 | 3.4 ± 2.1 mm | 72 | 97.2 | 2 | 2.77 | 13, 17.1 mm | 3.75, 5 mm | 1 and 3 weeks after procedure | 6–8 months | |
| 28 | 4.92 ± 1.24 mm | 26 | 96.15 | 1 | 3.84 | NM | 3.8, 5.0 mm | 2 weeks after procedure | 15.9 ± 2.94 months. | |
| 112 | 3.8 ± 2.1 mm | 219 | 95 | 11 FR = 5% | 5 | 13, 17.1 mm | 3.75, 5 mm | At 6 months after procedure | 13 months | |
| 20 | 2–6 mm | 37 | 100 | 0 | 0 | 13 mm | 5 mm | 18 months | ||
| 40 | 8.00 ± 2.19 mm | 56 | 100 | 0 | 0 | 11.5, 13, and 15 mm | 4.00, 6.50 mm | 1 year | ||
| 6 | 2.1–4.1 mm | 6 | 100 | 0 | 0 | 10, 11.5 mm | 4.2, 5.2 mm | 1 year (after prosthetic loading) | ||
| Gonzalez et al.[ | 14 | 5.2 mm | 11 | 90 | 1 | 10 | 13 mm | NM | 1 year | 1 year |
| Dhandapani et al. [ | 9 | 5–8 mm | NM | NM | NM | NM | NM | NM | NM | 6 months |
| Asmael and Lateef [ | 13 | 2.3–7.8 mm | 23 | 91.30 | 2 | 8.70 | 10, 12 mm | 4.2, 4.3, 4.8, and 5 mm | At 1 and 6 months | 1 year |
MIAMBE minimally invasive antral membrane balloon elevation, N number, NM not mentioned